Fibrinogen: A predictor of stroke and marker of atherosclerosis

European Heart Journal

Volumn 24, Issue 6, 2003, Pages 499-500

  Eidelman, Rachel S ^a   Hennekens, Charles H ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN;

AGE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; FIBRINOGEN BLOOD LEVEL; GENDER; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STROKE;

ADULT; AGED; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; FIBRINOGEN; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 0037343590     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00810-2     Document Type: Editorial

References (8)

1. Wilhelmsen L, Svärdsudd K, Korsan-Benstsen K et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
2. Meade TO, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
3. Thompson SG, Keinast J, Pyke SDM et al., for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
4. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998;97:1095-102.
5. Ridker PM, Rifai N, Stampfer MJ et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101: 1767-72.
6. Kofoed SC, Wittrup HH, Sillesen H et al. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis, but not echolucent, rupture-prone carotid plaques. Eur Heart J 2003; 24:567-76.
7. Hennekens CH, Buring J. Epidemiology in medicine. Boston: Little Brown, 1987.
8. The Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102:21-7.